Selecta Biosciences To Present At Two Upcoming Investor Conferences In November

WATERTOWN, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that Werner Cautreels, Ph.D., President, CEO and Chairman, will present at two upcoming investor conferences in November:
  • Stifel 2016 Healthcare Conference: Corporate presentation at 2:15 p.m. ET on Tuesday, November 15, 2016 in New York, NY.
  • 28th Annual Piper Jaffray Healthcare Conference: Fireside chat at 2:00 p.m. ET on Wednesday, November 30, 2016 in New York, NY.

A live and archived webcast will be available on the Investors & Media section of the Selecta website at www.selectabio.com.

About Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP-based products to either induce antigen-specific tolerance or activate the immune system.

Selecta's focus and strategy is to leverage its SVP immune modulating platform to develop and commercialize highly differentiated life-sustaining biologic drugs that are uniquely capable of mitigating the formation of anti-drug antibodies (ADAs). Proprietary programs that use SVP-Rapamycin to enhance efficacy and safety of therapy include SEL-212, Selecta's lead Phase 2 clinical program in chronic refractory gout, and two gene therapies programs for genetic metabolic diseases. Tolerance-inducing SVP biological products also have potential applications in the treatment of allergies and autoimmune diseases.